Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2007-08-14
2007-08-14
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S244100, C424S234100, C424S184100, C514S002600, C530S300000, C530S350000, C530S825000, C435S069300
Reexamination Certificate
active
10759600
ABSTRACT:
The present invention provides methods for eliciting an immune response against Group Astreptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group AstreptococciM proteins (which are capable of stimulating a protective immune response against Group Astreptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group Astreptococci.
REFERENCES:
patent: 4284537 (1981-08-01), Beachey
patent: 4454121 (1984-06-01), Beachey
patent: 4521334 (1985-06-01), Beachey
patent: 4597967 (1986-07-01), Beachey
patent: 4705684 (1987-11-01), Beachey
patent: 4784948 (1988-11-01), Scott et al.
patent: 4919930 (1990-04-01), Beachey et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5985654 (1999-11-01), Fischetti et al.
patent: 6063386 (2000-05-01), Dale et al.
patent: 6419932 (2002-07-01), Dale
patent: WO 94/06421 (1994-03-01), None
patent: WO 94/06465 (1994-03-01), None
patent: WO 00/37648 (2000-06-01), None
Ada,Fundamental Immunology, William E. Paul, M.D. (ed.), 2ndEdition, Raven Press, New York, 1989, pp. 1010-1011.
Baird et al., “Epitopes Of Group A Streptococcal M Protein Shared With Antigens Of Articular Cartilage And Synovim,”The Journal Of Immunology 149(9):3132-3137, 1991.
Beachey and Ofek, “Epithelial Cell Binding Of Group A Streptococci By Lipoteichoic Acid On Fimbriae Denuded Of M Protein,”The Journal Of Experimental Medicine 143:759-771, 1976.
Beachey and Seyer, “Protective And Nonprotective Epitopes Of Chemically Synthesized Peptides Of The NH2-Terminal Region Of Type 6 Streptoccal M Protein,”The Journal Of Immunology 136(6):2287-2292, 1986.
Beachey and Seyer,Seminars in Infectious Disease. vol. IV Bacterial Vaccines, Thieme-Stratton Inc., New York, New York, 1982, Chapter Fifty-Seven, “Primary Structure And Immuno-Chemistry Of Group A Streptoccal M Proteins,” pp. 401-410.
Beachey and Stollerman, “Mediation of Cytotoxic Effects of Streptococcal M Protein by Nontype-Specific Antibody in Human Sera,”The Journal of Clinical Investigation 52: 2563-2570, 1973.
Beachey and Stollerman, “Toxic Effects Of Steptococcal M Protein On Platelets And Polymorphonuclear Leukocytes In Human Blood,”The Journal Of Experimental Medicine 134: 351-365, 1971.
Beachey et al., “Human Immune Response To Immunization With a Structurally Defined Polypeptide Fragment Of Streptococcal M Protein,”J. Exp. Med. 150:862-877, 1979.
Beachey et al., “Immunogenicity In Animals And Man Of A Structurally Defined Polypeptide Of Streptococcal M Protein,”Transactions Of The Association Of American Physicians, vol. XCII:pp. 346-354, 1979.
Beachey et al., “Opsonic Antibodies Evoked By Hybrid Peptide Copies Of Types 5 and 24 Streptococcal M Proteins Synthesized In Tandem,”J. Exp. Med. 163: 1451-1458, 1986.
Beachey et al., “Peptic Digestion of Streptococcal M Protein. II. Extraction of M Antigen from Group A Streptococci With Pepsin,”Infection And Immunity 9(5):891-896, 1974.
Beachey et al., “Primary Structure of Protective Antigens of Type 24 Streptococcal M Protein,”The Journal Of Biological Chemistry 255(13):6284-6289, 1980.
Beachey et al., “Protective Immunogenicity And T Lymphocyte Specificity Of A Trivalent Hybrid Peptide Containing NH2-Terminal Sequences Of Types 5, 6, And 24 M Proteins Synthesized In Tandem,”The Journal Of Experimental Medicine 166:647-656, 1987.
Beachey et al., “Purification And Properties Of M Protein Extracted From Group A Streptococci With Pepsin: Covalent Structure Of The Amino Terminal Region Of Type 24 M Antigen,”The Journal Of Experimental Medicine 145:1469-1483, 1977.
Beachey et al., “Repeating Covalent Structure and Protective Immunogenicity of Native and Synthetic Polypeptide Fragments of Type 24 Streptococcal M Protein,”The Journal Of Biological Chemistry 258(21):13250-13257, 1983.
Beachey et al., “Repeating covalent structure of streptococcal M protein,”Proc. Natl. Acad. Sci. USA 75(7):3163-3167, 1978.
Beachey et al., “Separation Of The Type Specific M Protein From Toxic Cross Reactive Antigens Of Group A Streptococci,”Transactions Of The Association Of American Physicians. Ninetieth Session vol. XC: pp. 390-400, 1977.
Beachey et al., “Type-specific protective immunity evoked by synthetic peptide ofStreptococcus pyogenesM Protein,”Nature(London) 292:457-459, 1981.
Beall et al., “Sequencing emm-Specific PCR Products for Routine and Accurate Typing of Group A Streptococci,”Journal of Clinical Microbiology 34(4):953-958, Apr. 1996.
Blenden et al., “Growth ofListeria monocytogenesin a Corn Silage Extract Medium,”American Journal Of Veterinary Research 29(11):2237-2242, 1968.
Bricas et al., “Structure Et Synthese De La Subunite Peptide De La Paroi De Trois Bacteries Gram-Postif,”Peptides. Proceedings of the Eight European Peptide Symposium Sep. 1966,Noordwijk, Neth., North-Holland Publishing Company: Amsterdam, Neth. And Interscience Publishers Division, John Wiley and Sons, Inc., New York, 1967, 286-292 (+Biological Abstracts 50(4):Abstract No. 20361, 1936).
Bronze et al., “Protective And Heart-Cross Reactive Epitopes Located Within The NH2Terminus Of Type 19 Streptococcal M Protein,”The Journal Of Experimental Medicine 167:1849-1859, 1988.
Chou and Fasman, “Prediction of Protein Confirmation,”Biochemistry 13(2):222-245, 1974.
Cunningham and Beachey, “Peptic Digestion of Streptococcal M Protein. I. Effect of Digestion at Suboptimal pH upon the Biological and Immunochemical Properties of Purified M Protein Extracts,”Infection And Immunity 9(2):244-248, 1974.
Cunningham et al., “Human And Murine Antibodies Cross-Reactive With Streptococcal M Protein And Myosin Recognize The Sequence Gln-Lys-Ser-Lys-Gln In M Protein,”The Journal Of Immunology 143(8):2677-2683, 1989.
Dale, “Group A Streptococcal Vaccines,”New Vaccines And New Vaccine Technology 13(1):227-243, 1999.
Dale, “Group A Streptococcal Vaccines,”Pediatric Annals 27:301-308, 1998.
Dale, “Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments,”Vaccine 17:193-200, 1999.
Dale and Beachey, “Multiple, Heart-Cross-Reactive Epitopes Of Streptococcal M Proteins,”Journal OF Experimental Medicine 161:113-122, Jan. 1985.
Dale and Beachey, “Epitopes Of Streptococcal M Proteins Shared With Cardiac Myosin,”The Journal Of Experimental Medicine 162:583-591, 1985.
Dale and Beachey, “Localization Of Protective Epitopes Of The Amino Terminus Of Type 5 Streptococcal M Protein,”The Journal Of Experimental Medicine 163:1191-1202, 1986.
Dale and Beachey, “Sequence Of Myosin-Crossreactive Epitopes Of Streptococcal M Protein,”Journal Of Experimental Medicine 164:1785-1790, 1986.
Dale et al., “Heterogencity Of Type-Specific And Cross-Reactive Antigenic Determinants Within A Single M Protein Of Group A Streptococci,”The Journal Of Experimental Medicine 151:1026-1038, 1980.
Dale et al., “Blastogenic Responses Of Human Lymphocytes To Structurally Defined Polypeptide Fragments Of Streptococcal M Protein,”The Journal Of Immunology 126(4):1499-1505, 1981.
Dale et al., “Type-Specific Immunogenicity Of A Chemically Synthesized Peptide Fragment Of Type 5 Streptococcal M Protein,”The Journal Of Experimental Medicine 158:1727-1732, 1983.
Dale et al., “Recombinant Tetravalent Group A Streptococcal M Protein Vaccine,”Journal of Immunology 151(4):2188-2194, Aug. 15, 1993.
Dale et al., “Intranasal immunizatio
Devi S.
Seed IP Law Group PLLC
University of Tennessee Research Foundation
LandOfFree
Group A streptococcal vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group A streptococcal vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group A streptococcal vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3873757